{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:50:25Z","timestamp":1788731425148,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.ajo.2008.09.022","type":"journal-article","created":{"date-parts":[[2008,12,4]],"date-time":"2008-12-04T05:13:57Z","timestamp":1228367637000},"page":"703-708.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Inhibitory Effects of Trastuzumab on Corneal Neovascularization"],"prefix":"10.1016","volume":"147","author":[{"given":"Mete","family":"G\u00fcler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgut","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim","family":"\u00d6zercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Elkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2008.09.022_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ajo.2008.09.022_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib3","first-page":"502","article-title":"Laser photocoagulation of feeder vessels in lipid keratopathy","volume":"17","author":"Mendelsohn","year":"1986","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.ajo.2008.09.022_bib4","first-page":"291","article-title":"Q-switched Nd:YAG laser treatment for corneal neovascularization","volume":"36","author":"Goto","year":"1992","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib5","first-page":"1954","article-title":"Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization","volume":"38","author":"BenEzra","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2008.09.022_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/exer.1998.0512","article-title":"The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization","volume":"67","author":"Benelli","year":"1998","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2008.09.022_bib7","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajo.2008.09.022_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002800050885","article-title":"Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo","volume":"43","author":"Bocci","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ajo.2008.09.022_bib9","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1073\/pnas.90.7.2690","article-title":"Genistein, a dietary-derived inhibitor of in vitro angiogenesis","volume":"90","author":"Fotsis","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajo.2008.09.022_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00417-002-0591-7","article-title":"Inhibition of experimental angiogenesis of cornea by somatostatin","volume":"241","author":"Wu","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0002-9394(79)90245-9","article-title":"Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas","volume":"87","author":"Deutsch","year":"1979","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","article-title":"Topical application of methotrexate for inhibition of corneal angiogenesis","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib14","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1167\/iovs.05-1425","article-title":"Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits","volume":"47","author":"Shi","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2008.09.022_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00595-003-2710-4","article-title":"Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents","volume":"34","author":"Kim","year":"2004","journal-title":"Surg Today"},{"key":"10.1016\/j.ajo.2008.09.022_bib17","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1093\/annonc\/mdi905","article-title":"Therapy of breast cancer with molecular targeting agents","volume":"16","author":"Gasparini","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajo.2008.09.022_bib18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0002-9440(10)64253-8","article-title":"Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas","volume":"161","author":"Baker","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ajo.2008.09.022_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2008.09.022_bib20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularization by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.09.022_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ico.0000248385.16896.34","article-title":"Alkali-induced corneal neovascularization is independent of CXCR2-mediated neutrophil infiltration","volume":"26","author":"Lu","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.ajo.2008.09.022_bib22","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2008.09.022_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ajo.2008.09.022_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.8-suppl_3-5","article-title":"Signal events: Cell signal transduction and inhibition in cancer","volume":"8","author":"Rowinsky","year":"2003","journal-title":"The Oncologist"},{"key":"10.1016\/j.ajo.2008.09.022_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90276-3","article-title":"Mechanism of action of trastuzumab and scientific update","volume":"28","author":"Baselga","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ajo.2008.09.022_bib26","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/annonc\/12.suppl_1.S21","article-title":"Modulation of p27\/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling","volume":"12","author":"Lane","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajo.2008.09.022_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ajo.2008.09.022_bib28","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2005.00.661","article-title":"Neoadjuvant trastuzumab induces apoptosis in primary breast cancers","volume":"23","author":"Mohsin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajo.2008.09.022_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1012999012192","article-title":"DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines","volume":"70","author":"Mayfield","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajo.2008.09.022_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ajo.2008.09.022_bib31","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/cncr.11656","article-title":"Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone","volume":"98","author":"Klos","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ajo.2008.09.022_bib32","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1158\/1078-0432.CCR-04-0777","article-title":"Herceptin down-regulates HER-2\/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo","volume":"11","author":"Guan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajo.2008.09.022_bib33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/416279b","article-title":"Tumour biology: herceptin acts as an anti-angiogenic cocktail","volume":"21","author":"Izumi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ajo.2008.09.022_bib34","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/0008-5472.CAN-06-3155","article-title":"Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways","volume":"67","author":"Niu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajo.2008.09.022_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.ajo.2008.09.022_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ajo.2008.09.022_bib37","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1158\/1078-0432.CCR-06-0646","article-title":"Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs","volume":"12","author":"Ono","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajo.2008.09.022_bib38","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.soncn.2007.10.005","article-title":"Managing treatment side effects in advanced breast cancer","volume":"23","author":"Moore","year":"2007","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ajo.2008.09.022_bib39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939408007496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939408007496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:57:47Z","timestamp":1757595467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939408007496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0002939408007496"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2008.09.022","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Inhibitory Effects of Trastuzumab on Corneal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2008.09.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}